Of course you wouldn’t pay 39% more.  But Pfizer recently did. New York-based Pfizer (PFE) agreed to acquire Hospira (HSP).  Pfizer will pay $90 per share in cash, which represents a 39% premium to HSP’s closing price from the day before.  The companies put the … Continue reading Would You Pay 39% More Than The Asking Price?